Related Experiment Video
Updated: Oct 13, 2025
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
10.9K
BCL2 super-expressor diffuse large B-cell lymphoma: a distinct subgroup associated with poor prognosis
Jin Roh1, Hyungwoo Cho2, Hyo-Kyung Pak3
1Department of Pathology, Ajou University School of Medicine, Suwon, Korea.
Summary
Defining BCL2 super-expression through immunohistochemistry identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) with significantly worse survival outcomes. This finding highlights a potential new therapeutic target for DLBCL patients.
Area of Science:
- Hematology
- Oncology
- Molecular Pathology
Background:
- Overexpression of BCL2 protein is a known poor prognostic factor in diffuse large B-cell lymphoma (DLBCL).
- Current criteria for evaluating BCL2 protein expression lack standardization, hindering consistent prognostic assessment.
- Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is a standard first-line treatment for DLBCL.
Purpose of the Study:
- To establish standardized criteria for evaluating BCL2 protein expression using immunohistochemistry (IHC) in de novo DLBCL patients.
- To assess the prognostic value of BCL2 expression, specifically defining 'BCL2 super-expressors', in patients treated with R-CHOP.
- To investigate the association of BCL2 super-expression with survival outcomes and genetic aberrations.
Main Methods:
- Immunohistochemistry (IHC) was used to evaluate BCL2 protein expression, considering both staining intensity and proportion of positive cells.
- Patients with de novo DLBCL treated with first-line R-CHOP were categorized into 'BCL2 super-expressors' and 'non-BCL2 super-expressors'.
- Survival analyses (event-free survival and overall survival) were performed, adjusting for established prognostic factors like IPI and COO.
Main Results:
- BCL2 super-expressors (defined by strong, uniform IHC staining in nearly all tumor cells) exhibited significantly worse event-free survival (EFS) and overall survival (OS).
- The adverse prognostic impact of BCL2 super-expression was independent of the International Prognostic Index (IPI), cell of origin (COO), and MYC expression.
- Genetic analysis revealed that BCL2 super-expressors were enriched in NOTCH and TP53 signaling pathway aberrations.
Conclusions:
- The definition of BCL2 super-expression by IHC identifies a distinct molecular subset of DLBCL with a poor prognosis.
- This classification holds prognostic value irrespective of IPI, COO, MYC expression, and disease stage.
- BCL2 super-expression warrants further investigation as a potential therapeutic target, particularly for BCL-2 inhibitors.
